Romiplostim clinical trials
Also written Nplate, AMG 531 and GNR-069.
How each study uses romiplostim is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the romiplostim studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Aug 2008 · NPLATE · BLA 125268 (FDA, Drugs@FDA)
- European Union
- 4 Feb 2009 · Nplate · EMEA/H/C/000942 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
90 studies that test it; most in 2026 (13)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 5 |
| 2006 | 8 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 5 |
| 2015 | 5 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 8 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 10 |
| 2026 | 13 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 52
Amgen (25) · Peking Union Medical College Hospital (6) · Kyowa Kirin Co., Ltd. (5) · Memorial Sloan Kettering Cancer Center (4) · The First Affiliated Hospital of Soochow University (3) · Geropharm (2) · Anjali Sharathkumar (2) · AO GENERIUM (2)
Often tested with
Tested in the same studies.
Eltrombopag (3) · Rituximab (3) · Dexamethasone (2) · Cyclosporine (2) · Thrombopoietin Receptor Agonist (1) · Adrenal Cortex Hormones (1) · Immunoglobulins (1) · Prednisolone (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test romiplostim.
- Nov 2026Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBTPhase 2 · Anhui Provincial Hospital
- Jan 2027Single Arm Romiplostim to Prevent CITEarly Phase 1 · Children's Hospital Medical Center, Cincinnati
- Jan 2027Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of LeukemiaPhase 2 · Anhui Provincial Hospital
- Feb 2027Combination Therapy of Romiplostim and Erythropoiesis-stimulating AgentsPhase 2 · Chinese University of Hong Kong
- Feb 2027Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune ThrombocytopeniaNot applicable · The First Affiliated Hospital of Soochow University
- Aug 2027Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid TumorsPhase 2 · Zhujiang Hospital
- Sep 2027Romiplostim for Oral TPO-RA Resistant ITPNot applicable · The First Affiliated Hospital of Soochow University
Studies
Open first, then newest update. How each study uses romiplostim is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 90
- Romiplostim for Platelet Engraftment After Haploidentical or Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell TransplantationRecruitingPhase 2Liping DouNCT07919977Written as Romiplostim
- Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.RecruitingPhase 2Nantes University HospitalNCT07278661Written as Nplate
- Combination Therapy of Romiplostim and Erythropoiesis-stimulating AgentsRecruitingPhase 2Chinese University of Hong KongNCT07854561Written as Romiplostim
- Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingPhase 2The First Affiliated Hospital of Henan University of Science and TechnologyNCT07829952Written as Romiplostim N01
- A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)RecruitingPhase 3AmgenNCT07700238Written as Romiplostim
- Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of LeukemiaRecruitingPhase 2Anhui Provincial HospitalNCT06898983Written as Romiplostim N01
- Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast CancerNot yet recruitingPhase 2Fudan UniversityNCT07771881Written as Romiplostim N01
- Romiplostim for Oral TPO-RA Resistant ITPRecruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT07612319Written as Romiplostim
- Romiplostim N01 in Chemoradiotherapy-induced Aplastic AnemiaNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07572084Written as Romiplostim N01
- Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer PatientsRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07043894Written as Romiplostim N01
- CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAANot yet recruitingPhase 2Peking Union Medical College HospitalNCT07558434Written as Romiplostim N01
- Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AARecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07400341Written as Romiplostim
- A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11RecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT06759636Written as Romiplostim N01
- Single Arm Romiplostim to Prevent CITRecruitingEarly Phase 1Children's Hospital Medical Center, CincinnatiNCT07048249Written as Romiplostim (AMG-531)
- Romiplostim N01 for Platelet Recovery After Haploidentical HSCTRecruitingPhase 1First Affiliated Hospital of Zhejiang UniversityNCT07321626Written as Romiplostim N01
- A Study of Romiplostim N01 Plus IST vs. Placebo Plus IST for Treatment-Naive Severe Aplastic AnemiaNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07345000Written as Romiplostim N01
- Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune ThrombocytopeniaRecruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT07206823Written as Romiplostim N01
- A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid TumorsNot yet recruitingNot applicableJun wangNCT07185893Written as Romiplostim N01
- Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer PatientsNot yet recruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT07162519Written as romiplostim N01
- Romiplostim N01 for the Treatment of Thrombocytopenia Associated With Radiotherapy-Combined Treatment Regimens in Patients With Solid TumorsNot yet recruitingPhase 2Zhujiang HospitalNCT07128576Written as Romiplostim N01
See all 90 studies that test romiplostim →
Given beside what is tested · 5 — romiplostim is usual care or a partner of the new treatment
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06345495Written as Romiplostim
- Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid TumorsRecruitingPhase 2Peking University People's HospitalNCT07586813Written as Romiplostim N01
- Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsRecruitingPhase 2Peking University People's HospitalNCT07586826Written as Romiplostim N01
- Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of TherapyNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07400250Written as Romiplostim N01
- Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAANot yet recruitingPhase 4Peking Union Medical College HospitalNCT06009497Written as Romiplostim
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call romiplostim · ClinicalTrials.gg INT004684
- MeSH (NLM) C488777romiplostimOne source NLM
- UNII (FDA) GN5XU2DXKVROMIPLOSTIMConfirmed FDA, NLM, Wikidata
- RxNorm 805452Confirmed FDA, Wikidata
- Wikidata Q1235195romiplostimConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C52183RomiplostimConfirmed FDA, Wikidata
- DrugBank DB05332One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C488777 | romiplostim | One source NLM |
| UNII (FDA) | GN5XU2DXKV | ROMIPLOSTIM | Confirmed FDA, NLM, Wikidata |
| RxNorm | 805452 | — | Confirmed FDA, Wikidata |
| Wikidata | Q1235195 | romiplostim | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C52183 | Romiplostim | Confirmed FDA, Wikidata |
| DrugBank | DB05332 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.